369 SOUTH SAN ANTONIO RD., LOS ALTOS, CA
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. Enters Underwriting Agreement for $93.9 Million Offering
Alto Neuroscience Reports $244.2 Million Cash as of June 30, 2026
Appointment of Andrew Miller, Ph.D. to Board of Directors
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Reports Full Year 2025 Financial Results and Recent Business Highlights
Announces $120 Million Private Placement Financing
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Definitive Revised Proxy Statement